Factive
(Gemifloxacin)ApprovedSmall molecule
Factive is one of 8 small molecule programs targeting Gonorrhea. It is currently in Approved.
1
Indications
4
Total Trials
1
Active Trials
7
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Gonorrhea
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Garamycin
SSchering-Plough
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Factive
LLG Chem
Approved
Menacwy Liquid
GSKPreclinical
Trumenba
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Rhinoscleroma1 trial
Comparison Between Rifampicin and Gemifloxacin and Ciprofloxacin in Treatment of Rhinoscleroma
Unknown status·—·Phase 1·NCT03326050·60 enrolled
Gonorrhea1 trial
Efficacy of Combination Therapies for Gonorrhea Treatment
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00926796·614 enrolled
Peritonitis1 trial
Regulatory
FDA Approval Timeline[4]
Apr 4, 2003
FACTIVE
NDA NDA021158
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gemifloxacin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]